DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 03:20:12 2024-06-13 am EDT | ||
| 39.28 EUR | -0.13% |
|
| Current month | +4.60% | ||
| 1 month | -2.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-13 | 39.28 | -0.13% |
| 24-06-12 | 39.33 | -1.30% |
| 24-06-11 | 39.85 | +1.19% |
| 24-06-10 | 39.38 | +2.93% |
| 24-06-07 | 38.26 | +1.92% |
Delayed Quote Deutsche Boerse AG
Last update June 13, 2024 at 03:20 am EDT
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PE2NCW |
| ISIN | DE000PE2NCW5 |
| Date issued | 2022-09-21 |
| Maturity | 2024-06-21 (9 Days) |
| Parity | 1 : 1 |
| Emission price | 39.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 41.63 € |
|---|---|
| Lowest since issue | 36.83 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.41
USD
Average target price
53.19
USD
Spread / Average Target
+25.43%
- Stock Market
- Certificates
- Certificat
